GOSSAMER BIO INC (GOSS) Stock Price & Overview
NASDAQ:GOSS • US38341P1021
Current stock price
The current stock price of GOSS is 0.3459 USD. Today GOSS is down by -6.51%. In the past month the price decreased by -30.92%. In the past year, price decreased by -58.07%.
GOSS Key Statistics
- Market Cap
- 80.062M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.75
- Dividend Yield
- N/A
GOSS Stock Performance
GOSS Stock Chart
GOSS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GOSS. When comparing the yearly performance of all stocks, GOSS is a bad performer in the overall market: 98.21% of all stocks are doing better.
GOSS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GOSS. GOSS may be in some trouble as it scores bad on both profitability and health.
GOSS Earnings
On March 17, 2026 GOSS reported an EPS of -0.21 and a revenue of 13.80M. The company missed EPS expectations (-5.22% surprise) and beat revenue expectations (79.84% surprise).
GOSS Forecast & Estimates
16 analysts have analysed GOSS and the average price target is 4.44 USD. This implies a price increase of 1182.74% is expected in the next year compared to the current price of 0.3459.
For the next year, analysts expect an EPS growth of 27.45% and a revenue growth -31.58% for GOSS
GOSS Groups
Sector & Classification
GOSS Financial Highlights
Over the last trailing twelve months GOSS reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS decreased by -188.46% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -98.91% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GOSS Ownership
GOSS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.93 | 365.463B | ||
| AMGN | AMGEN INC | 15.01 | 184.669B | ||
| GILD | GILEAD SCIENCES INC | 15.85 | 173.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.325B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.32 | 80.669B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.27 | 43.81B | ||
| INSM | INSMED INC | N/A | 35.309B | ||
| NTRA | NATERA INC | N/A | 29.036B | ||
| BIIB | BIOGEN INC | 10.72 | 25.293B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.74 | 24.53B | ||
| MRNA | MODERNA INC | N/A | 19.261B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.898B | ||
| INCY | INCYTE CORP | 12.39 | 18.878B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GOSS
Company Profile
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
Company Info
IPO: 2019-02-08
GOSSAMER BIO INC
3115 Merryfield Row, Suite 120
San Diego CALIFORNIA 92121 US
CEO: Faheem Hasnain
Employees: 144
Phone: 13026365400
GOSSAMER BIO INC / GOSS FAQ
What does GOSS do?
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
What is the current price of GOSS stock?
The current stock price of GOSS is 0.3459 USD. The price decreased by -6.51% in the last trading session.
Does GOSSAMER BIO INC pay dividends?
GOSS does not pay a dividend.
What is the ChartMill rating of GOSSAMER BIO INC stock?
GOSS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for GOSS stock?
16 analysts have analysed GOSS and the average price target is 4.44 USD. This implies a price increase of 1182.74% is expected in the next year compared to the current price of 0.3459.
What is GOSSAMER BIO INC worth?
GOSSAMER BIO INC (GOSS) has a market capitalization of 80.06M USD. This makes GOSS a Micro Cap stock.
What is the outstanding short interest for GOSSAMER BIO INC?
The outstanding short interest for GOSSAMER BIO INC (GOSS) is 16.76% of its float.